Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Huoxue Zhitong is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Traditional Chinese Medicine, specifically designed for the treatment of cardiovascular diseases such as coronary heart disease and angina pectoris. The formula is rooted in the TCM principle of supplementing Qi (vital energy) and activating blood circulation to resolve stasis and alleviate pain, targeting the 'Qi deficiency and blood stasis' syndrome common in chronic heart conditions. Pharmacologically, the drug is thought to improve myocardial ischemia, enhance vascular endothelial function, and exert anti-inflammatory and anti-platelet effects. Clinical studies conducted at the developing institution have demonstrated its efficacy in reducing the frequency and severity of angina attacks and improving the overall quality of life for patients with stable and unstable angina.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi huoxue zhitong.